| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $246,928 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Rudick Richard Alan | director | 1 | $100,024 | 0 | $0 | $100,024 |
| Neermann Joerg | director | 2 | $76,700 | 0 | $0 | $76,700 |
| Whaley Glenn | Chief Financial Officer | 1 | $32,076 | 0 | $0 | $32,076 |
| Nash Duane | Executive Chairman | 1 | $16,694 | 0 | $0 | $16,694 |
| Vitt Daniel | CEO and Director | 1 | $11,550 | 0 | $0 | $11,550 |
| Tardio Jason | President and COO | 1 | $9,884 | 0 | $0 | $9,884 |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Over the last 12 months, insiders at Immunic, Inc. have bought $246,928 and sold $0 worth of Immunic, Inc. stock.
On average, over the past 5 years, insiders at Immunic, Inc. have bought $177,402 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rudick Richard Alan (director) — $100,024. Neermann Joerg (director) — $76,700. Whaley Glenn (Chief Financial Officer) — $32,076.
The last purchase of 20,000 shares for transaction amount of $16,694 was made by Nash Duane (Executive Chairman) on 2025‑06‑13.
| 2025-06-13 | Nash Duane | Executive Chairman | 20,000 0.0216% | $0.83 | $16,694 | -3.28% | ||
| 2025-06-05 | Neermann Joerg | director | 30,000 0.0308% | $0.76 | $22,800 | +0.91% | ||
| 2025-06-05 | Tardio Jason | President and COO | 12,512 0.0133% | $0.79 | $9,884 | +0.91% | ||
| 2025-06-04 | Neermann Joerg | director | 70,000 0.0726% | $0.77 | $53,900 | +0.63% | ||
| 2025-06-04 | Vitt Daniel | CEO and Director | 15,000 0.0156% | $0.77 | $11,550 | +0.63% | ||
| 2025-06-03 | Rudick Richard Alan | director | 143,075 0.1429% | $0.70 | $100,024 | +6.78% | ||
| 2025-06-03 | Whaley Glenn | Chief Financial Officer | 45,000 0.0458% | $0.71 | $32,076 | +6.78% | ||
| 2024-11-12 | Rudick Richard Alan | director | 87,300 0.0969% | $1.15 | $100,369 | -16.45% | ||
| 2024-02-26 | Vitt Daniel | President and CEO | 14,000 0.0159% | $1.31 | $18,333 | -0.78% | ||
| 2023-05-15 | Whaley Glenn | Chief Financial Officer | 5,000 0.0114% | $1.75 | $8,750 | -22.16% | ||
| 2022-12-14 | Neermann Joerg | director | 47,000 0.1472% | $1.26 | $59,032 | +29.37% | ||
| 2022-12-13 | Neermann Joerg | director | 35,000 0.1105% | $1.25 | $43,610 | +31.45% | ||
| 2022-11-23 | Neermann Joerg | director | 18,000 0.0578% | $1.39 | $25,020 | +19.85% | ||
| 2022-11-22 | Vitt Daniel | President and CEO | 8,000 0.0259% | $1.35 | $10,799 | +24.43% | ||
| 2022-11-07 | Whaley Glenn | Chief Financial Officer | 5,000 0.0164% | $1.50 | $7,475 | +13.99% | ||
| 2022-06-03 | Vitt Daniel | President and CEO | 5,000 0.0151% | $3.10 | $15,500 | -43.22% | ||
| 2022-06-03 | Whaley Glenn | Chief Financial Officer | 3,500 0.0104% | $3.04 | $10,658 | -43.22% | ||
| 2022-05-12 | Muehler Andreas | Chief Medical Officer | 3,500 0.0115% | $5.10 | $17,850 | -59.81% | ||
| 2022-05-12 | Nash Duane | Executive Chairman | 10,000 0.0323% | $5.03 | $50,300 | -59.81% | ||
| 2022-05-12 | Whaley Glenn | Chief Financial Officer | 3,000 0.0098% | $5.08 | $15,240 | -59.81% |
| Rudick Richard Alan | director | 230375 0.2334% | $211,322.99 | 2 | 0 | <0.0001% |
| Neermann Joerg | director | 200000 0.2027% | $183,460.00 | 5 | 0 | +26.89% |
| Whaley Glenn | Chief Financial Officer | 95510 0.0968% | $87,611.32 | 8 | 0 | <0.0001% |
| Nash Duane | Executive Chairman | 36032 0.0365% | $33,052.15 | 6 | 1 | +26.35% |
| Vitt Daniel | CEO and Director | 29000 0.0294% | $26,601.70 | 5 | 2 | +11.82% |
| Tardio Jason | President and COO | 12512 0.0127% | $11,477.26 | 1 | 0 | |
| Muehler Andreas | Chief Medical Officer | 297986 0.302% | $273,342.56 | 2 | 0 | <0.0001% |
| Groeppel Manfred | Chief Operating Officer | 278830 0.2825% | $255,770.76 | 0 | 2 | |
| Winters Terence E. | Co-Chairman and CEO | 194966 0.1976% | $178,842.31 | 2 | 0 | +75.81% |
| SEARS LOWELL | director | 58572 0.0594% | $53,728.10 | 2 | 0 | |
| BIENAIME JEAN JACQUES | director | 18500 0.0187% | $16,970.05 | 6 | 2 | +135.14% |
| CROXFORD PHILIP M | director | 17841 0.0181% | $16,365.55 | 1 | 0 | |
| DUNN JOHN MICHAEL | General Counsel and Secretary | 11885 0.012% | $10,902.11 | 3 | 0 | +35.39% |
| Hasnain Faheem | director | 4500 0.0046% | $4,127.85 | 2 | 1 | |
| Ashley Robert A. | Chief Technical Officer, EVP | 2000 0.002% | $1,834.60 | 1 | 0 | +69.53% |
| Stern Aron | See Remarks | 1333 0.0014% | $1,222.76 | 1 | 0 | |
| Satter Muneer A | 0 0% | $0 | 22 | 3 | +61.06% | |
| Godshall Douglas Evan | director | 0 0% | $0 | 2 | 1 | |
| Cohen Cheryl | director | 0 0% | $0 | 1 | 1 | +12.02% |
| Halperin Errol R. | director | 0 0% | $0 | 2 | 1 |
$5,262,089 | 154 | 5.62% | $96.13M | |
$30,470,407 | 140 | 20.39% | $100.96M | |
$9,405,928 | 107 | 12.61% | $94.27M | |
$155,630,608 | 79 | -24.53% | $93.43M | |
$4,898,715 | 46 | 40.75% | $87.35M | |
$18,994,888 | 46 | 88.59% | $105.08M | |
$77,146,704 | 43 | 13.28% | $96.63M | |
$909,129 | 37 | 42.19% | $81.23M | |
$140,595,157 | 34 | 17.93% | $103.73M | |
Immunic, Inc. (IMUX) | $36,180,184 | 32 | 41.36% | $90.52M |
$1,602,584 | 20 | 15.26% | $78.63M | |
$33,128,160 | 18 | -13.64% | $79.13M | |
$20,234,041 | 17 | 2.09% | $80.25M | |
$11,267,080 | 15 | -22.36% | $82.41M | |
$17,741,707 | 13 | 30.23% | $82.81M | |
$1,073,250 | 10 | 19.46% | $96.3M | |
$5,524,590 | 7 | 7.40% | $101.83M | |
$110,013 | 5 | 6.58% | $77.26M | |
$112,382,168 | 4 | -48.89% | $88.96M |
| Increased Positions | 25 | +40.32% | 10M | +22.36% |
| Decreased Positions | 17 | -27.42% | 6M | -14.23% |
| New Positions | 10 | New | 5M | New |
| Sold Out Positions | 11 | Sold Out | 5M | Sold Out |
| Total Postitions | 70 | +12.9% | 48M | +8.13% |
| Aberdeen Group Plc | $4,806.00 | 6.87% | 8.24M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $4,462.00 | 6.38% | 7.65M | 0 | 0% | 2025-09-30 |
| Avidity Partners Management Lp | $2,740.00 | 3.92% | 4.7M | -916,400 | -16.32% | 2025-09-30 |
| Vanguard Group Inc | $2,533.00 | 3.62% | 4.35M | +219,957 | +5.33% | 2025-09-30 |
| Morgan Stanley | $1,809.00 | 2.59% | 3.1M | -525,406 | -14.48% | 2025-09-30 |
| Focus Partners Wealth | $1,505.00 | 2.15% | 2.58M | +39,063 | +1.54% | 2025-09-30 |
| Laurion Capital Management Lp | $1,097.00 | 1.57% | 1.88M | -22,901 | -1.2% | 2025-09-30 |
| Soleus Capital Management, L.P. | $921.00 | 1.32% | 1.58M | -6M | -78.33% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $815.00 | 1.17% | 1.4M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $603.00 | 0.86% | 1.03M | +59,136 | +6.07% | 2025-09-30 |